Aton Group announces the appointment of Hadrien Lanvin as Deputy CEO. Having served on the group's board since December 2023, Lanvin will assist in enhancing the value of the group's assets, which specialize in life sciences and medical technologies.
Hadrien Lanvin, a graduate of HEC Paris and the founder-CEO of Evora Biosciences, assumes his new role as Deputy CEO of Aton. Serving on the group's board since December 2023, he has gained a deep understanding of the group's assets and their markets through his board involvement.
Primary Mission at Aton
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
In his new role, Hadrien Lanvin's main task will be to support the enhancement of Aton Group's asset values by improving the clarity of their strategic positioning, markets, and development prospects. He will work closely with the leadership teams of the subsidiaries to support their growth trajectory and enhance their visibility within the financial and industrial ecosystem.
Related
SectorIndustrie Pharmaceutique et Biotechnologie›Biotechnologie
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
